ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Broder Says No Thanks To Acknowledgement For Paper’s Title

June 6, 1997

Continuing Resolution Averts Shutdown; Locks in Sequestration Cuts for NIH, NCI

March 22, 2013

DeLap: Seven Years In industry Provided View Of Pressures On Drug Developers

August 2, 1996

Blood Cancers Advocacy Groups Seek DOD And NCI Funds, Medicare Coverage.

July 6, 2001

ODAC Votes 10-0 In Favor Of Avastin For Recurrent Glioblastoma Multiforme

April 3, 2009

Harkin Withdraws Amendment Allow NIH To Bypass INDS

October 9, 1992